79 related articles for article (PubMed ID: 15913565)
1. Chronic Delta9-tetrahydrocannabinol treatment produces antinociceptive tolerance in mice without altering protein kinase A activity in mouse brain and spinal cord.
Dalton GD; Smith FL; Smith PA; Dewey WL
Biochem Pharmacol; 2005 Jul; 70(1):152-60. PubMed ID: 15913565
[TBL] [Abstract][Full Text] [Related]
2. The role of several kinases in mice tolerant to delta 9-tetrahydrocannabinol.
Lee MC; Smith FL; Stevens DL; Welch SP
J Pharmacol Exp Ther; 2003 May; 305(2):593-9. PubMed ID: 12606657
[TBL] [Abstract][Full Text] [Related]
3. Alterations in brain Protein Kinase A activity and reversal of morphine tolerance by two fragments of native Protein Kinase A inhibitor peptide (PKI).
Dalton GD; Smith FL; Smith PA; Dewey WL
Neuropharmacology; 2005 Apr; 48(5):648-57. PubMed ID: 15814100
[TBL] [Abstract][Full Text] [Related]
4. Protein Kinase A activity is increased in mouse lumbar spinal cord but not brain following morphine antinociceptive tolerance for 15 days.
Dalton GD; Smith FL; Smith PA; Dewey WL
Pharmacol Res; 2005 Sep; 52(3):204-10. PubMed ID: 16026714
[TBL] [Abstract][Full Text] [Related]
5. Reversal of delta 9-tetrahydrocannabinol-induced tolerance by specific kinase inhibitors.
Bass CE; Welch SP; Martin BR
Eur J Pharmacol; 2004 Aug; 496(1-3):99-108. PubMed ID: 15288581
[TBL] [Abstract][Full Text] [Related]
6. Changes in opioid and cannabinoid receptor protein following short-term combination treatment with delta(9)-tetrahydrocannabinol and morphine.
Cichewicz DL; Haller VL; Welch SP
J Pharmacol Exp Ther; 2001 Apr; 297(1):121-7. PubMed ID: 11259535
[TBL] [Abstract][Full Text] [Related]
7. Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol.
Cichewicz DL; Welch SP
J Pharmacol Exp Ther; 2003 Jun; 305(3):812-7. PubMed ID: 12606610
[TBL] [Abstract][Full Text] [Related]
8. Ras/ERK signalling in cannabinoid tolerance: from behaviour to cellular aspects.
Rubino T; Forlani G; Viganò D; Zippel R; Parolaro D
J Neurochem; 2005 May; 93(4):984-91. PubMed ID: 15857401
[TBL] [Abstract][Full Text] [Related]
9. [Changes of AC/cAMP system and phosphorylation regulation of adenylate cyclase activity in brain regions from morphine-dependent mice].
Fang F; Wang Q; Cao Q; Liu J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Feb; 22(1):14-9. PubMed ID: 12903486
[TBL] [Abstract][Full Text] [Related]
10. Protein kinase A contributes to sciatic ligation-associated early activation of cyclic AMP response element binding protein in the rat spinal dorsal horn.
Miletic G; Hanson EN; Savagian CA; Miletic V
Neurosci Lett; 2004 Apr; 360(3):149-52. PubMed ID: 15082155
[TBL] [Abstract][Full Text] [Related]
11. Evidence for the involvement of glutamatergic and GABAergic systems and protein kinase A pathway in the antinociceptive effect caused by p-methoxy-diphenyl diselenide in mice.
Pinto LG; Jesse CR; Nogueira CW; Savegnago L
Pharmacol Biochem Behav; 2008 Feb; 88(4):487-96. PubMed ID: 18023853
[TBL] [Abstract][Full Text] [Related]
12. Chronic treatment with Delta(9)-tetrahydrocannabinol impairs spatial memory and reduces zif268 expression in the mouse forebrain.
Boucher AA; Vivier L; Metna-Laurent M; Brayda-Bruno L; Mons N; Arnold JC; Micheau J
Behav Pharmacol; 2009 Feb; 20(1):45-55. PubMed ID: 19179850
[TBL] [Abstract][Full Text] [Related]
13. Modulation of extracellular signal-regulated kinases cascade by chronic delta 9-tetrahydrocannabinol treatment.
Rubino T; Forlani G; Viganò D; Zippel R; Parolaro D
Mol Cell Neurosci; 2004 Mar; 25(3):355-62. PubMed ID: 15033164
[TBL] [Abstract][Full Text] [Related]
14. Antinociceptive activity of Delta9-tetrahydrocannabinol non-ionic microemulsions.
Lazzari P; Fadda P; Marchese G; Casu GL; Pani L
Int J Pharm; 2010 Jun; 393(1-2):238-43. PubMed ID: 20399844
[TBL] [Abstract][Full Text] [Related]
15. Adrenomedullin enhances baroreceptor reflex response via cAMP/PKA signaling in nucleus tractus solitarii of rats.
Ho LK; Chen K; Ho IC; Shen YC; Yen DH; Li FC; Lin YC; Kuo WK; Lou YJ; Yen JC
Neuropharmacology; 2008 Oct; 55(5):729-36. PubMed ID: 18616957
[TBL] [Abstract][Full Text] [Related]
16. Regulation of DARPP-32 phosphorylation by Delta9-tetrahydrocannabinol.
Borgkvist A; Marcellino D; Fuxe K; Greengard P; Fisone G
Neuropharmacology; 2008 Jan; 54(1):31-5. PubMed ID: 17686497
[TBL] [Abstract][Full Text] [Related]
17. Despite strong behavioral disruption, Delta9-tetrahydrocannabinol does not affect cell proliferation in the adult mouse dentate gyrus.
Kochman LJ; dos Santos AA; Fornal CA; Jacobs BL
Brain Res; 2006 Oct; 1113(1):86-93. PubMed ID: 16930565
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic factors in sex differences in Delta 9-tetrahydrocannabinol-induced behavioral effects in rats.
Tseng AH; Harding JW; Craft RM
Behav Brain Res; 2004 Sep; 154(1):77-83. PubMed ID: 15302113
[TBL] [Abstract][Full Text] [Related]
19. Behavioral cross-tolerance between repeated intracerebellar nicotine and acute Delta(9)-tetrahydrocannabinol-induced cerebellar ataxia: role of cerebellar nitric oxide.
Smith AD; Dar MS
J Pharmacol Exp Ther; 2007 Jul; 322(1):243-53. PubMed ID: 17416741
[TBL] [Abstract][Full Text] [Related]
20. DFP initiated early alterations of PKA/p-CREB pathway and differential persistence of beta-tubulin subtypes in the CNS of hens contributes to OPIDN.
Damodaran TV; Gupta RP; Attia MK; Abou-Donia MB
Toxicol Appl Pharmacol; 2009 Oct; 240(2):132-42. PubMed ID: 19664648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
